Role of testosterone in managing advanced prostate cancer

Urology

Volumn 80, Issue 4, 2012, Pages 754-762

  Rove, Kyle O ^a   Debruyne, Frans M ^b   Djavan, Bob ^c   Gomella, Leonard G ^d   Koul, Hari K ^a   Lucia, M Scott ^a   Petrylak, Daniel P ^e   Shore, Neal D ^f   Stone, Nelson N ^g   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Andros Men's Health Institutes   (Netherlands)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f Carolina Urologic Research   (United States)

^g MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROSTANOLONE; DOCETAXEL; GONADORELIN AGONIST; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ADVANCED CANCER; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER NECK STENOSIS; BONE METASTASIS; BONE PAIN; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; CELL PROLIFERATION; CLINICAL DECISION MAKING; DEPRESSION; GENE EXPRESSION; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORCHIECTOMY; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SEXUAL DYSFUNCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84866737033     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.05.006     Document Type: Review

References (55)

1. M.R. Cooperberg, G.D. Grossfeld, D.P. Lubeck National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989
2. C. Huggins, C.V. Hodges Studies on prostate cancer: I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
3. G. Andriole, N. Bruchovsky, L.W. Chung Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia J Urol 172 2004 1399 1403
4. E.D. Crawford Understanding the epidemiology, natural history, and key pathways involved in prostate cancer Urology 73 2009 S4 S10
5. A.W. Hsing Hormones and prostate cancer: what's next? Epidemiol Rev 23 2001 42 58
6. A.W. Roddam, N.E. Allen, P. Appleby Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170 183
7. I. Takizawa, T. Nishiyama, N. Hara Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: tumor malignant potential and androgen milieu Prostate 70 2010 1395 1401
8. A. Salonia, A. Gallina, A. Briganti Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy Cancer 117 2011 3953 3962
9. C.C. Schulman, J. Irani, J. Morote Testosterone measurement in patients with prostate cancer Eur Urol 58 2010 65 74
10. S.T. Page, D.W. Lin, E.A. Mostaghel Persistent intraprostatic androgen concentrations after medical castration in healthy men J Clin Endocrinol Metab 91 2006 3850 3856
11. T. Nishiyama, Y. Hashimoto, K. Takahashi The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer Clin Cancer Res 10 2004 7121 7126
12. A. Morgentaler, A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth Eur Urol 55 2009 310 320
13. P.J. Saylor, M.R. Smith Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer J Natl Compr Cancer Netw 8 2010 211 223
14. G. Corona, M. Gacci, E. Baldi Androgen deprivation therapy in prostate cancer: Focusing on sexual side effects J Sex Med 9 2012 887 902
15. C.J. Nelson, J.S. Lee, M.C. Gamboa Cognitive effects of hormone therapy in men with prostate cancer: a review Cancer 113 2008 1097 1106
16. H. Bonkhoff, R. Berges From pathogenesis to prevention of castration resistant prostate cancer Prostate 70 2010 100 112
17. J.A. Locke, E.S. Guns, A.A. Lubik Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 2008 6407 6415
18. B.Y. Bao, J.B. Pao, C.N. Huang Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy Clin Cancer Res 17 2011 928 936
19. M. Stanbrough, G.J. Bubley, K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
20. N. Sharifi, W.L. Dahut, W.D. Figg The genetics of castration-resistant prostate cancer: what can the germline tell us? Clin Cancer Res 14 2008 4691 4693
21. W. Rosner, H. Vesper, R. Azziz Toward excellence in testosterone testing: a consensus statement J Clin Endocrinol Metab 95 2010 4542 4548
22. W. Rosner, R.J. Auchus, R. Azziz Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement J Clin Endocrinol Metab 92 2007 405 413
23. A.M. Matsumoto, W.J. Bremner Serum testosterone assays - accuracy matters J Clin Endocrinol Metab 89 2004 520 524
24. C. Wang, D.H. Catlin, L.M. Demers Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry J Clin Endocrinol Metab 89 2004 534 543
25. Testosterone, LC/MS/MS test summary 2011 Quest Diagnostics®
26. Testosterone, total, women, children, and hypogonadal males, LC/MS-MS 2011 Laboratory Corporation of America®
27. H.W. Vesper, S. Bhasin, C. Wang Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods Steroids 74 2009 498 503
28. G. Novara, A. Galfano, S. Secco Impact of surgical and medical castration on serum testosterone level in prostate cancer patients Urol Int 82 2009 249 255
29. M.G. Oefelein, A. Feng, M.J. Scolieri Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
30. A. Zlotta, F. Debruyne Expert opinion on optimal testosterone control in prostate cancer Eur Urol Suppl 4 2005 37 41
31. B.J. Lin, K.K. Chen, M.T. Chen The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer Urology 43 1994 834 837
32. N.R. Zinner, M. Bidair, A. Centeno Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial Urology 64 2004 1177 1181
33. L. Klotz, L. Boccon-Gibod, N.D. Shore The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531 1538
34. N. Mottet, J. Bellmunt, M. Bolla EAU guidelines on prostate cancer Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
35. B. Tombal, R. Berges Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy Eur Urol Suppl 7 2008 15 28
36. E.D. Crawford, K.O. Rove, M. Brawer Determination of clinical characteristics for men on ADT as related to baseline serum testosterone levels J Urol 185 2011 e67
37. J. Morote, S. Esquena, J.M. Abascal Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer Urol Int 77 2006 135 138
38. L.G. Gomella Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol 11 2009 52 60
39. T. Pickles, S. Tyldesly Testosterone breakthrough during LHRH agonist androgen deprivation with curative radiation: impact on PSA kinetics and subsequent biochemical outcomes Presented at the 26th Annual Congress of the European Association of Urology Vienna, Austria 2011
40. J. Morote, J. Planas, C. Salvador Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy BJU Int 103 2009 332 335
41. National Comprehensive Cancer Network Clinical practice guidelines in oncology Prostate cancer, version 1 http://www.nccn.org/professionals/physician- gls/pdf/prostate.pdf Accessed March 8, 2012
42. J. Seidenfeld, D.J. Samson, V. Hasselblad Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 2000 566 577
43. J. Morote, A. Orsola, J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295
44. M. Perachino, V. Cavalli, F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105 2010 648 651
45. D.A. Loblaw, K.S. Virgo, R. Nam Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605
46. R.B. Montgomery, E.A. Mostaghel, R. Vessella Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
47. K.O. Rove, T.W. Flaig A renaissance in the medical treatment of advanced prostate cancer Oncology 24 2010 1 11
48. P.A. Abrahamsson Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49 59
49. L. Klotz, J. O'Callaghan, K. Ding A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK intercontinental trial CRUKE/01/013 J Clin Oncol 29 suppl 7 2011
50. E.Y. Yu, R. Gulati, D. Telesca Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation J Clin Oncol 28 2010 2668 2673
51. F.E. Calais da Silva, A.V. Bono, P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269 1277
52. J.M. Blumberg, E.O. Kwon, T.C. Cheetham Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer Urology 77 2011 412 416
53. ZYTIGA® (Abiraterone Acetate) Tablets Full Prescribing Information 2011 Janssen Biotech
54. A. Molina, A. Belldegrun Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling J Urol 185 2011 787 794
55. H.I. Scher, K. Fizazi, F. Saad Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study J Clin Oncol 30 2012 LBA1